This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker's (BRKR) Research Tools Enable New insight on PACS
by Zacks Equity Research
Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
by Zacks Equity Research
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
by Zacks Equity Research
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.
Here's Why You Should Hold on to Avanos (AVNS) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS), owing to its strong product line and focus on its R&D.
National Vision (EYE) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
According to National Vision (EYE), increased demand for low-cost eye exams, glasses and contact lenses boosts first-quarter performance.
Haemonetics (HAE) Q4 Earnings Lag Estimates, Gross Margin Dips
by Zacks Equity Research
Haemonetics' (HAE) fourth-quarter fiscal 2021 revenues declined 5.6% year over year due to the pandemic.
The Zacks Analyst Blog Highlights: Amazon, Tesla, NextEra Energy, CME Group and Boston Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Tesla, NextEra Energy, CME Group and Boston Scientific
Top Analyst Reports for Amazon, Tesla & NextEra
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Amazon.com (AMZN), Tesla (TSLA), and NextEra Energy (NEE).
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
by Zacks Equity Research
The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1
by Zacks Equity Research
Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips
by Zacks Equity Research
Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.
Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT (XENT) first-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
Here's Why You Should Buy Boston Scientific (BSX) Stock Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid first-quarter performance and impressive value-added acquisitions.
LHC Group (LHCG) Loses 1.1% In Spite of Q1 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in hospice admissions.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
Zimmer Biomet's (ZBH) Recovery to Continue Despite Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.
Medtronic (MDT) to Enhance Patient Care via Digital Portal
by Zacks Equity Research
Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from segmental strength in the first quarter.
Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1
by Zacks Equity Research
Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.
Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat
by Zacks Equity Research
Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.